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We report the presence of adenosine receptors at  
molecular level and study their role in the inflamma-
tory pathway under hyperglycemic condition. Human 
Muller cells were cultured in low (5 mM) and high 
(25 mM) glucose with 10% FBS and 1% P/S. Cells 
were starved in 0% FBS for 18 h and then treated 
with various agonists CCPA, CGS 21680, NECA and 
IB-MECA for 6, 12 and 24 h. The adenosine receptors 
were identified by immunocytochemistry. ELISA was 
used to measure the levels of TNF-, IL-1 and ICAM 
1. Four types of adenosine receptors (A1, A2A, A2B and 
A3) were identified in human Muller cells. TNF- con-
tent increased after agonist A1 and A3 treatment, but 
decreased after agonist A2A and A2B treatment. There 
was no significant effect on ICAM-1 and IL-1. Stimu-
lation of human Muller cells with adenosine A2A ago-
nist (CGS 21680) and adenosine A2B agonist (NECA) 
reduces the level of TNF- when exposed to high glu-
cose, whereas A1 adenosine agonist (CCPA) and A3 
adenosine agonist (IB-MECA) both positively and 
negatively regulate the TNF- in hyperglycemia. 
However, none of these agonists has any significant 
role in affecting ICAM-1 and IL-1. 
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DIABETIC retinopathy (DR) is one of the most common 
complications of diabetes, causing vision impairment and 
blindness1,2. According to the International Diabetes  
Federation, diabetes currently affects 366 million people 
in the world and the number will rise to 552 million by 
2030. Diabetic retinopathy has been classified as nonpro-
liferative diabetic retinopathy (NPDR) and proliferative 
diabetic retinopathy (PDR)3,4. Some characteristics of 
diabetic retinopathy include basement membrane thicken-
ing, alteration in blood flow, loss of retinal pericytes, in-
creased proliferation of endothelial cells and formation of 
microaneurysms4–6. Progression through these stages 
leads to neovascularization and eventually loss of vision. 
The mechanism by which the diabetic risk factors initiate 
vascular disruption and disease progression in retinopathy 
remains unclear. However, in vivo and in vitro studies 
have shown diabetic retinopathy has features of inflam-
mation which involve activation of multiple mediators 
such as adhesion molecules, chemokines and pro-
inflammatory cytokines in migration of leukocytes to-
wards infected or injured tissue7. During inflammation, 
the infected or injured tissue releases pro-inflammatory 
cytokines (tumour necrosis factor-alpha (TNF-), inter-
leukin-1-beta 1 (IL-1) and chemokines (CCL 2 and CCL 
5)), which induce the coordinate expression of numerous 
adhesion molecules such as E-selectin, intracellular adhe-
sion molecules (ICAM)-1, vascular adhesion molecules 
(VCAM)-1 and chemokines4–7. 
 Although pathogen does not play any role in diabetic 
retinopathy, research has been carried out on the vitreous 
fluid, serum, cells and diabetic animal models to demon-
strate the upregulation of pro-inflammatory cytokines, 
chemokines and adhesion molecules in diabetic retinopa-
thy. Increased level of IL-1 has been observed in the  
vitreous fluid of patients with diabetic retinopathy, retina 
from diabetic rats and retinal endothelial8–11. The expres-
sion of TNF- markedly increased in vitreous, serum, 
ocular fibrovascular membranes from diabetic patients 
and in retina from animal models with diabetes melli-
tus12–14. It has been reported that retinal Muller cells play 
an important role in the initiation and progression of  
diabetic-retinopathy15,16. Muller cells are the principal 
glial cell of the retina which serve as structural support 
cells and spans its entire thickness17. According to some 
studies, Muller cells have a role in regulating blood flow 
in the retina and maintaining the blood retinal barrier 18,19. 
Inflammatory markers present in glial cells of the retina 
are significantly induced in hyperglycemic conditions. 
 Adenosine is an endogenous purine nucleoside that is 
formed at sites of metabolic stress associated with injury 
or inflammation20,21. Its effects are being mediated 
through four types of receptors which are A1, A2A, A2B 
and A3 (ref. 22). These receptors are members of the G-
protein-coupled receptors (GPCRs), which are actively 
involved in downstream signalling of various pathways. 
A1 and A3 receptors are coupled to inhibitory G protein 
(Gi/0), and their stimulation decreases the intracellular cy-
clic adenosine monophosphate (cAMP) concentration, 
whereas A2A and A2B are coupled to stimulatory G protein 
(Gs), and their stimulation increases cAMP concentration. 
It has been reported that A1 and A2A are activated by low 
concentration (0.01–1 M), whereas A2B and A3 need 
higher volume (> 10 m)23–25. In the present study, we 
mimic the hyperglycemic condition by growing the cells 
in high glucose and determine the presence of adenosine 
receptors in human Muller cells and the effect of their 
agonists on inflammatory markers under hyperglycemic 
condition. 
 Human Muller cells MIO-M1 were isolated from the 
neural retina of cadaveric donor eyes obtained from 
Moorfields Hospital Eye Bank26. Cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 
10% (vol/vol), fetal bovine serum (FBS) and 1% (vol/ 
vol) penicillin/streptomycin in a humidified atmosphere 
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Figure 1. Detection of adenosine receptors in human Muller cells (MIO-M1). a, Adenosine receptors in high glucose. b, Adenosine receptors in 
low glucose. The cells were grown in DMEM containing low glucose (5 mM) and high glucose (25 mM) with 10% FBS for 48 h. Goat anti-actin 
antibodies were used as positive control. The images are representative of three independent experiments. 
 
 
with 5% CO2. For the experiment, the cells were grown 
in DMEM containing 5 mM glucose (low glucose) and 
25 mM glucose (high glucose) with 10% FBS for 48 h, 
and then starved for 18 h in medium containing 0% FBS. 
Subsequently the cells were treated with 2-chloro- 
N6-cyclopentyladenosine (CCPA) (adenosine A1 ago-
nist), CGS 21680 (adenosine A2A agonist), 5-(N-ethyl-
carboxamido) adenosine (NECA) (adenosine A2B agonist) 
and N6-(3-iodobenzyl) adenosine-5-N-methyluronamide 
(IB-MECA) (adenosine A3 agonist) at three different 
concentrations (1, 10 and 100 M) for 6, 12 and 24 h  
respectively. 
 The adenosine receptors were identified as described 
earlier27, with modifications. Muller cells were seeded 
(50,000/well) onto six-well tissue culture plates contain-
ing sterile coverslips in a medium containing low glucose 
(5 mM) and high glucose (25 mM) and allowed to attach 
and proliferate in the respective medium for 2 days. The 
cells were fixed with cold methanol for 10 min at –20C, 
rinsed twice with PBS, blocked at room temperature with 
0.5% Tween (v/v) and 2% BSA (w/v) in PBS (blocking 
solution) for 1 h and rinsed twice with PBS. The cells 
were incubated overnight with primary antibodies (anti-
A1 receptor, anti-A2A receptor, anti-A2B receptor and 
anti-A3 receptor) in blocking solution 1  : 100. Goat anti-
actin antibodies were used as positive control . The fol-
lowing day, cells were washed twice with PBS and incu-
bated for 1 h in a dark room with secondary antibodies 
conjugated with fluorescein isothiocyanate (FITC) in 
blocking solution at 1 :  200. After rinsing twice with PBS, 
the coverslips were mounted with antifading medium 
(ProLong Gold, Life Technologies, USA). 
 For preparation of cell lysates, the cells were washed 
with cold PBS and the monolayer was scrapped into 
250 l of lysis buffer (Mammalian Cell Lysis Kit, Sigma, 
USA)28. The total cell lysates were centrifuged at 
12,000 g for 10 min at 4C and the supernatant was fro-
zen at –20C. Protein concentration of the supernatant 
was quantified with the Bradford (Bio-Rad) protein assay. 
 ELISA was performed for TNF-, IL-1 and ICAM-1 
(R&D Systems, USA) according to the manufacturer’s 
instruction. Drugs CCPA, CGS 21680, NECA and IB-
MECA were procured from Sigma. All stock solutions 
were prepared in dimethylsulphoxide (DMSO) and stored 
at –20C until used. 
 Results were expressed as mean  SEM. Student’s t-
test was used to evaluate the results. P < 0.05 was con-
sidered statistically significant. 
 Before studying whether adenosine agonists alter  
inflammatory marker levels in human Muller cells (MIO-
M1), we first determined the presence of adenosine  
receptors by immunofluorescence technique using  
specific anti-A1, anti-A2A, anti-A2B and anti-A3 anti-
bodies (Figure 1). All subtypes of adenosine receptors are 
present in human Muller cells (MIO-M1). 
 TNF- levels were increased in high glucose levels 
compared with low glucose (P < 0.05, Figure 2 a). Stimu-
lation with CCPA (1 M) significantly increased the 
TNF- content after 6 h of treatment (P < 0.05, Figure 
2 b), while 10 and 100 M of CCPA decreased the TNF-
 content. However, 12 h of treatment with 1 and 
100 M of CCPA significantly reduced the level of TNF-
, but 10 M significantly increased the level of TNF- 
(P < 0.05, Figure 2  b). After 24 h, 1 and 10 M of CCPA 
increased the TNF- content, but 100 M significantly 
reduced the expression of TNF- (P < 0.05, Figure 2 b). 
These results suggest that stimulation of human Muller 
cells in a hyperglycemic condition with CCPA can  
decrease/increase production of TNF-. Stimulation with 
CGS 21680 (1, 10 and 100 M), significantly decreased 
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TNF- levels at 6 h after treatment in human Muller cells 
cultured in hyperglycemia (P < 0.05, Figure 2  c).  
However, the production of TNF- increased after being 
treated with CGS 21680 (1, 10 and 100 M) at 12 h. At 
24 h, 1 M of CGS 21680 significantly reduced the ex-
pression of TNF- (P < 0.05, Figure 2  c). Similarly 
10 M of CGS 21680 decreased the TNF- content, but 
100 M of CGS 21680 remained high. Based on these 
findings, stimulation of human Muller cells in a hyper-
glycemic condition with 1 M of CGS 21680 can  
decrease production of TNF-. Stimulation with NECA 
(1 M) decreased the TNF- content after 6 h of treat-
ment but there was no significant reduction, while 10 M 
of NECA significantly decreased the expression of TNF-
 (P < 0.05, Figure 2 d) and 100 M of NECA increased 
the level of TNF-. After 12 h of treatment with 1 M of 
NECA, the level of TNF- decreased, while 10 and 
100 M of NECA significantly decreased the level of 
TNF- (P < 0.05, Figure 2  d). After 24 h, 1 M of NECA 
increased the TNF- content, but 10 and 100 M reduced 
the expression of TNF-. Our results revealed that stimu-
lation of human Muller cells in a hyperglycemic condi-
tion with 10 M of NECA can decrease the production of 
TNF-. Stimulation with IB-MECA (1, 10 and 100 M), 
decreased TNF- levels at 6 h after treatment in human  
 
 
 
 
Figure 2. ELISA of TNF- in human Muller cells (a) grown in low 
and high glucose without treatment as a control, (b) treated with 1, 10 
and 100 M of CCPA for 6, 12 and 24 h respectively, (c) treated with 
1, 10 and 100 M of CGS 21680 for 6, 12 and 24 h respective ly, (d) 
treated with 1, 10 and 100 M of NECA for 6, 12 and 24 h respectively 
and (e) treated with 1 M, 10 M and 100 M of IB-MECA for 6, 12 and 
24 h respectively. Data are represented as mean  SEM. (a) *P < 0.05; 
high glucose compared to low glucose. (b–e) *P < 0.05; treated com-
pared with control. 
Muller cells cultured in hyperglycemia, but significantly 
with 100 M of IB-MECA (P < 0.05, Figure 2 e). After 
12 h of treatment with 1 M and 10 M of IB-MECA, the 
level of TNF- decreased significantly (P < 0.05, Figure 
2 e) and 100 M of IB-MECA increased the expression of 
TNF- (P < 0.05, Figure 2  e). Also, 24 h of treatment 
with IB-MECA (1 M) significantly increased the  
expression of TNF-, while 10 and 100 M decreased the 
TNF- content. Our results demonstrated that stimulation 
of human Muller cells in a hyperglycemic condition with 
IB-MECA can decrease/increase production of TNF-. 
 Human Muller cells grown in high glucose and low 
glucose did not alter IL-1 levels (Figure 3  a). The  
expression of IL-1 significantly increased after 24 h 
treatment with CCPA (1, 10 and 100 M). Stimulation 
with NECA (10 M) significantly increased IL-1 levels 
at 12 h after treatment in MIO-M1 cells cultured in high 
glucose medium (P < 0.05 versus non-treated; Figure 
3 d). 
 Human Muller cells grown in medium containing 5  
or 25 mM glucose and stimulated with four different 
adenosine agonists did not have altered levels of ICAM-1 
(Figure 4). 
 In the present study, we provide evidence that cultured 
human Muller cells express A1, A2A, A2B and A3  
 
 
 
Figure 3. ELISA of IL-1  in human Muller cells (a) grown in low 
and high glucose without treatment as a control, (b) treated with 1, 10 
and 100 M of CCPA for 6 , 12 and 24 h respectively, (c) treated with 
1, 10 and 100 M of CGS 21680 for 6, 12 and 24 h respective ly, (d) 
treated with 1, 10 and 100 M of NECA for 6, 12 and 24 h respectively 
and (e) treated with 1, 10 and 100 M of IB-MECA for 6, 12 and 24 h 
respective ly. Data are represented as mean  SEM. (a) *P < 0.05; high 
glucose compared to low glucose. (b–e) *P < 0.05; treated compared 
with control. 
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Figure 4. ELISA of ICAM-1 in human Muller cells (a) grown in low 
and high glucose without treatment as a control, (b) treated with 1, 10 
and 100 M of CCPA for 6, 12 and 24 h respectively, (c) treated with 
1, 10 and 100 M of CGS 21680 for 6, 12 and 24 h respective ly, (d) 
treated with 1, 10 and 100 M of NECA for 6, 12 and 24 h respectively 
and (e) treated with 1, 10 and 100 M of IB-MECA for 6, 12 and 24 h 
respective ly. Data are represented as mean  SEM. (a) *P < 0.05; high 
glucose compared to low glucose. (b–e) *P < 0.05; treated compared 
with control. 
 
 
adenosine receptors. Recent studies have shown that  
inflammation plays a major role in the pathogenesis of 
diabetic retinopathy29,30. Several inflammatory markers 
have been reported which might be involved in the 
pathogenesis of diabetic retinopathy, as mediators bet-
ween leukocytes or as regulators of leukocyte adhesion 
and activation in retinal tissue31. Here we have studied 
the effect of adenosine agonist on the inflammatory 
markers such as TNF-, IL-1 and ICAM-1 in hypergly-
cemic condition. 
 TNF- is known as a pro-inflammatory cytokine which 
can be found in many types of cells, including astrocytes, 
macrophages, microglia and retinal glial cells32. In 
agreement with other studies, our results demonstrate that 
stimulation of human Muller cells (MIO-M1) with adeno-
sine A2A agonist and adenosine A2B agonist can reduce 
the level of TNF- in hyperglycemia33–37. These findings 
suggest that both adenosine agonists A2A and A2B serve 
pro-inflammatory role in the development of diabetic 
retinopathy. However, stimulation with both adenosine 
agonists A1 and A3 positively and negatively regulates 
TNF- when exposed to high glucose concentration in  
vitro. These findings suggest that both A1 and A3 serve a 
dual role, pro-inflammatory and anti-inflammatory in the 
development of diabetic retinopathy. 
 The expression of IL-1 is known to be upregulated in 
the retina from diabetic rat, galactosemic mice and diabetic 
patients37,38. In addition, human monocytes, aortic, retinal 
vascular endothelial cells and Muller cells have been 
shown to upregulate IL-1 when exposed to high glucose 
concentration in vitro39–41. The present results showing no 
significant increases in IL-1 production, are in contrast 
to the recent work by Steinle et al.6 A possible explana-
tion for the discrepancy between our finding and the pre-
vious work is that we measured the IL-1 protein level 
after a short exposure (2 days) to high glucose, whereas 
the previous study measured the production of IL-1 after 
a prolonged exposure (5 days) to high glucose. In our re-
sults, similar to that of Liu et al., glucose induces IL-1 
expression in retinal vascular endothelial cells but not in 
Muller cells, astrocytes or microglia. Our study revealed 
that high glucose has no effect on ICAM-1, which is in 
agreement with the findings of Chen et al.42,43. 
 In conclusion, our studies show that A1, A2A, A2B and 
A3 adenosine receptors are expressed in human Muller 
cells (MIO-M1). Our study also demonstrates the pres-
ence of adenosine receptors in human Muller cells (MIO-
M1). Furthermore, our in vitro studies show that stimula-
tion of human Muller cells with adenosine A2A agonist 
(CGS 21680) and adenosine A2B agonist (NECA) can  
reduce the level of pro-inflammatory cytokines such as 
TNF- when exposed to high glucose, whereas A1 adeno-
sine agonist (CCPA) and A3 adenosine agonist (IB-
MECA) both positively and negatively (biphasic response) 
regulate TNF- in hyperglycemia. 
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